Overcoming critical barriers when developing mRNA-based cell therapies

In this roundtable discussion, panelists will share insights and lessons learned on how to overcome key barriers in the development and manufacture of mRNA-based cell therapies.

Register Free: https://www.pharmtech.com/pt_w/critical-barriers

Event Overview

There is a robust and promising therapeutic pipeline of mRNA-based cell therapies. This roundtable panel will discuss critical barriers in the drug substance development process for mRNA-based cell therapies. The discussion will include process development lessons learned, insights from analytical development programs, and how manufacturing innovations can help you navigate and overcome these key barriers.

Key Learning Objectives

Join this roundtable panel to learn how to overcome critical barriers when developing mRNA-based cell therapies. Specific topics include:

• Common challenges or barriers in the manufacture of mRNA for cell therapies
• Process development and manufacturing lessons learned and insights
• Critical steps in analytical development and characterization
• Key considerations and questions to ask when evaluating a potential manufacturing partner for mRNA-based cell therapies

Who Should Attend

Primary Audience: mRNA drug developers and professionals from biotechnology, emerging biopharma, and small to mid-sized pharma
Secondary Audience: mRNA professionals from higher education or academia
Job function: R&D, Process Development Scientists, Clinical Research and Supply, Clinical Operations, Quality Assurance, Procurement and Supply Chain

Speakers

Evan Myers
Associate Director of Process Development
TriLink BioTechnologies

Evan Myers is the Associate Director of Process Development at TriLink BioTechnologies, where he oversees the development of mRNA and pDNA. Evan has extensive experience in this area, having held various positions in mRNA and oligonucleotide manufacturing, GMP, and process development, where he supported several drug substances. His expertise spans biologics through synthesis, chromatography, scale-up, and process optimization covering development, manufacturing, and analytical testing.

Khaled Yamout
Senior Director of Analytical Services and Quality Control
TriLink Biotechnologies

Khaled Yamout is the Senior Director of Analytical Services and Quality Control at TriLink Biotechnologies where he oversees all analytical aspects of method development and validation to product release and stability to support regulatory filings for both small and large molecules. Prior to TriLink, Khaled held various positions in Quality Control, Research and Development, and Manufacturing where he supported a number of Drug substances and Drug products (both small molecules and biologics) from clinical phase to commercial. These include diverse experience and expertise ranging from discovery to manufacturing with Fortune 500 firms, as well as small entrepreneurial businesses in the areas of synthetic, analytical, colloidal, surface modification, protein, and antibody modification and purification covering both manufacturing and analytical testing and characterization.

Jordana Henderson
Associate Director of mRNA Research & Development
TriLink Biotechnologies

Jordana Henderson is the Associate Director of mRNA Research & Development at TriLink Biotechnologies where she oversees the development of optimized transcription reactions using novel modified cap analogs, evaluation of mutant or alternative RNA polymerases for reduced dsRNA formation, and upcoming innovative design technologies for mRNA platforms. She and her team also investigate ways to increase protein expression in various model systems. Jordana’s background is in molecular biology and she has contributed to TriLink’s mRNA services for 9 years.

Register Free: https://www.pharmtech.com/pt_w/critical-barriers